Indian experience with JAKi in Rheumatology

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Indian experience with JAKi in Rheumatology
The Indian experience with Janus kinase inhibitors (JAKi) in rheumatology has been increasingly positive, reflecting their growing role in managing autoimmune conditions like rheumatoid arthritis (RA) and ankylosing spondylitis (AS). JAK inhibitors, such as Tofacitinib and Baricitinib, have provided Indian rheumatologists with new tools to treat patients who do not respond adequately to traditional DMARDs or biologics. These oral medications offer the advantage of convenience and have shown significant efficacy in reducing inflammation, pain, and disease activity in a variety of rheumatic diseases.
However, the adoption of JAK inhibitors in India also presents challenges, particularly regarding cost and accessibility. While these drugs have been a game-changer for many patients, their high cost can be a barrier, limiting widespread use. Additionally, there is a need for increased awareness and education among healthcare providers about the appropriate use and monitoring of JAK inhibitors, given their potential side effects, such as an increased risk of infections and thromboembolic events. Despite these challenges, the integration of JAK inhibitors into rheumatology practice in India represents a significant advancement, offering new hope for patients with difficult-to-treat rheumatic diseases.
Therefore, get an overall knowledge of Indian experience with JAKi in rheumatology
 

See More Webinars @ Hidoc Webinars